Multiple endocrine neoplasia type 1 epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
(→Gender) |
(Mahshid) |
||
| (27 intermediate revisions by 5 users not shown) | |||
| Line 2: | Line 2: | ||
{{Multiple endocrine neoplasia type 1}} | {{Multiple endocrine neoplasia type 1}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
The [[prevalence]] of [[multiple endocrine neoplasia]] type-1 ([[MEN, type 1|MEN]]-1) is approximately 2-3 per 100,000 individuals worldwide. Patients of all age groups may develop [[Multiple endocrine neoplasia type 1|MEN-1]], but it is commonly [[Diagnose|diagnosed]] among patients between 18-50 years of age. [[Multiple endocrine neoplasia type 1|MEN-1]] affects men and women equally. There is no racial predilection to [[Multiple endocrine neoplasia type 1|MEN-1]]. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
==Prevalence== | ===Prevalence=== | ||
* Worldwide, the [[prevalence]] of | * Worldwide, the [[prevalence]] of [[Multiple endocrine neoplasia type 1|MEN-1]] is estimated to be 2-3 per 100,000.<ref>[http://www.hindawi.com/journals/jo/2012/705036/cta/] C. Romei, E. Pardi, F. Cetani, and R. Elisei, “Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2,” Journal of Oncology, vol. 2012, Article ID 705036, 15 pages, 2012. doi:10.1155/2012/705036</ref> | ||
== | ===Age=== | ||
* | * [[Endocrine]] and non-[[endocrine]] manifestations of the [[disease]] in [[Multiple endocrine neoplasia type 1|MEN-1]] patients most often begin in the fourth or fifth decade. | ||
* The onset of the [[disease]] is rare before 10 years of age.<ref name="pmiddoi:10.1016/j.beem.2010.07.003">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=doi:10.1016/j.beem.2010.07.003 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref><ref name="pmid17014705">{{cite journal| author=Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E et al.| title=Multiple endocrine neoplasia type 1. | journal=Orphanet J Rare Dis | year= 2006 | volume= 1 | issue= | pages= 38 | pmid=17014705 | doi=10.1186/1750-1172-1-38 | pmc=PMC1594566 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17014705 }} </ref> | |||
== | ===Gender=== | ||
* | * Men and women are affected equally by [[Multiple endocrine neoplasia type 1|MEN-1]].<ref name="pmiddoi:10.1016/j.beem.2010.07.003">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=doi:10.1016/j.beem.2010.07.003 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref><ref name="pmid21551167">{{cite journal| author=Goudet P, Bonithon-Kopp C, Murat A, Ruszniewski P, Niccoli P, Ménégaux F et al.| title=Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines. | journal=Eur J Endocrinol | year= 2011 | volume= 165 | issue= 1 | pages= 97-105 | pmid=21551167 | doi=10.1530/EJE-10-0950 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21551167 }} </ref> | ||
* Men have a higher [[incidence]] of [[pancreatic tumor]]s, whereas women have a higher [[incidence]] of [[pituitary tumor]]s. | |||
* Thymic [[tumor]]s are common among men. | |||
== | ===Race=== | ||
* There is no | * There is no racial predilection to [[Multiple endocrine neoplasia type 1|MEN-1]]. | ||
==References== | ==References== | ||
{{ | {{reflist|2}} | ||
[[Category: | [[Category:Oncology]] | ||
[[Category:Endocrinology]] | |||
{{ | {{WS}} | ||
{{ | {{WH}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 02:45, 27 November 2017
|
Multiple endocrine neoplasia type 1 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Multiple endocrine neoplasia type 1 epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 epidemiology and demographics |
|
FDA on Multiple endocrine neoplasia type 1 epidemiology and demographics |
|
CDC on Multiple endocrine neoplasia type 1 epidemiology and demographics |
|
Multiple endocrine neoplasia type 1 epidemiology and demographics in the news |
|
Blogs on Multiple endocrine neoplasia type 1 epidemiology and demographics |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [3]
Overview
The prevalence of multiple endocrine neoplasia type-1 (MEN-1) is approximately 2-3 per 100,000 individuals worldwide. Patients of all age groups may develop MEN-1, but it is commonly diagnosed among patients between 18-50 years of age. MEN-1 affects men and women equally. There is no racial predilection to MEN-1.
Epidemiology and Demographics
Prevalence
- Worldwide, the prevalence of MEN-1 is estimated to be 2-3 per 100,000.[1]
Age
- Endocrine and non-endocrine manifestations of the disease in MEN-1 patients most often begin in the fourth or fifth decade.
- The onset of the disease is rare before 10 years of age.[2][3]
Gender
- Men and women are affected equally by MEN-1.[2][4]
- Men have a higher incidence of pancreatic tumors, whereas women have a higher incidence of pituitary tumors.
- Thymic tumors are common among men.
Race
- There is no racial predilection to MEN-1.
References
- ↑ [1] C. Romei, E. Pardi, F. Cetani, and R. Elisei, “Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2,” Journal of Oncology, vol. 2012, Article ID 705036, 15 pages, 2012. doi:10.1155/2012/705036
- ↑ 2.0 2.1 Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID doi:10.1016/j.beem.2010.07.003 Check
|pmid=value (help). - ↑ Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E; et al. (2006). "Multiple endocrine neoplasia type 1". Orphanet J Rare Dis. 1: 38. doi:10.1186/1750-1172-1-38. PMC 1594566. PMID 17014705.
- ↑ Goudet P, Bonithon-Kopp C, Murat A, Ruszniewski P, Niccoli P, Ménégaux F; et al. (2011). "Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines". Eur J Endocrinol. 165 (1): 97–105. doi:10.1530/EJE-10-0950. PMID 21551167.